- Trial phase
- Approved
- Time to market
- Already marketed. Generic versions of Janumet XR launched in July 2026, and generic Janumet (non-XR) received FDA ANDA approval in 2026. The brand faces ongoing revenue erosion from generics and IRA-mandated price cuts effective January 1, 2027.
- Why 3/10
- Janumet is an already-approved, commercially marketed drug with no pending PDUFA or pivotal readout. The defining binary events (generic entry, patent cliff) have already occurred. The next notable date is the IRA price cut taking effect January 1, 2027, but this is a gradual commercial headwind, not a binary catalyst. Janumet is also a small and declining portion of Merck's $66B+ revenue base, so even major sales swings move the stock minimally.
Janumet is a post-peak, generically-eroded asset with no binary catalysts ahead. The IRA price cut on January 1, 2027, will further compress brand revenue, but this is well-telegraphed. For MRK investors, the focus should remain on Keytruda's Qlex launch trajectory, Gardasil demand in China, and pipeline readouts rather than the declining diabetes franchise, which is already a diminishing contributor to overall results.
Price Chart
Executive Summary
Janumet (sitagliptin/metformin) is Merck's long-approved combination diabetes pill that is now deep into its patent cliff. Generic versions launched in mid-2026, combined Januvia/Janumet franchise sales are declining roughly 30% year-over-year, and an IRA-mandated 85% Medicare price cut takes effect in January 2027. For Merck, a $144B market-cap diversified pharma giant, Janumet is a small and shrinking revenue stream. The stock's trajectory is driven far more by Keytruda, Gardasil, and the pipeline than by this declining legacy diabetes brand.
How It Works
Janumet is a combination pill containing two diabetes drugs: sitagliptin (a DPP-4 inhibitor that increases insulin release when blood sugar rises) and metformin (which lowers glucose production in the liver and improves insulin sensitivity). It is taken orally to manage type 2 diabetes alongside diet and exercise.
Trial Status
Janumet (immediate-release) and Janumet XR (extended-release) are both FDA-approved and have been commercially marketed for many years. No new pivotal clinical trials are underway for the brand; the drug is in its post-patent lifecycle phase.
The Two-Sided Case
Upcoming Catalysts
- IRA Medicare negotiated price for Janumet takes effect January 1, 2027 (85% cut to ~$80/month)
- Sitagliptin phosphate salt patent expires November 24, 2026 (pediatric exclusivity to May 24, 2027)
- Co-formulation patent expires January 21, 2029 (pediatric exclusivity to July 21, 2029)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report